Cost-effectiveness watchdogs in the U.K. dealt another couple of blows to pricey cancer drugs. The National Institute for Health and Care Excellence gave a final thumbs-down to Roche's ($RHHBY) breast cancer med Kadcyla, despite the drugmaker's discount offer. Agency reviewers also recommended against using Bristol-Myers Squibb's ($BMY) Opdivo in squamous non-small cell lung cancer, saying the immunotherapy was too costly for its admittedly notable clinical benefits. More from FiercePharma